Buprenorphine in the Emergency Department: Buprenorphine Versus Clonidine for Opioid Withdrawal
Overview
- Phase
- Phase 4
- Intervention
- Buprenorphine
- Conditions
- Opioid Withdrawal
- Sponsor
- St. Joseph's Health Centre Toronto
- Enrollment
- 26
- Primary Endpoint
- Number of participants attending the rapid access clinic
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
This is a pilot randomized control trial randomizing patients presenting in opioid withdrawal to the emergency department to receive either one of clonidine (usual standard of care) or buprenorphine for their opioid withdrawal. Primary treatment outcome is attendance at a rapid access addiction medicine clinic within a few days of emergency room presentation. Secondary treatment outcome is treatment status with respect to opioid agonist treatment at one month post emergency room visit.
Investigators
Anita Srivastava
Staff Physician and Associate Professor
St. Joseph's Health Centre Toronto
Eligibility Criteria
Inclusion Criteria
- •Presenting to the ED in opioid withdrawal or soon to be in withdrawal
- •Minimum age 16
- •English speaking
- •Active phone number
- •Ontario Health Insurance Program card
Exclusion Criteria
- •Currently enrolled in a methadone or buprenorphine maintenance
- •Benzodiazepine addiction (or taking \>50mg of valium equivalent/day)
- •Acute hepatitis or liver failure
Arms & Interventions
Buprenorphine
Patient receives buprenorphine in the emergency room based on a clinical trial protocol as well as a take home prescription for buprenorphine
Intervention: Buprenorphine
Clonidine
Patient receives clonidine in the emergency room based on a clinical trial protocol and also receives a take home prescription for clonidine
Intervention: Clonidine
Outcomes
Primary Outcomes
Number of participants attending the rapid access clinic
Time Frame: 2-5 days
The number of participants who attend a rapid access clinic assessment after initial enrollment
Secondary Outcomes
- Number of participants who are on opioid agonist treatment(30 days)